<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="624">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>29/09/2005</approvaldate>
  <actrnumber>ACTRN12605000556640</actrnumber>
  <trial_identification>
    <studytitle>Seroquel compared to Risperidone in the treatment of psychotic disorders adolescents.</studytitle>
    <scientifictitle>Randomised controlled clinical trial of the efficacy and tolerability of Seroquel compared to Risperidone in the treatment of psychotic disorders among 15-18 year old adolescents.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D1441C00019 </secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adolescent psychosis</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Quetiapine fumarate (titrate to between 400 and 800mg)

Risperidone (titrated to between 4-6mg)</interventions>
    <comparator>Risperidone is the comparator. Orally administered for a period of six weeks at a dose not exceeding 6 mg titrated according to clinical response.</comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>BPRS</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PANS</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CGI</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CGI-S Hamilton RSD</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Becks Depression Inventory</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Glodberg Mania Questionaire</outcome>
      <timepoint>On Days 2, 21, and 42</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Abnormal Involuntary Movements Scale</outcome>
      <timepoint>On days 2, 6, 10, 17, 21, 28, 35, 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Angus Simpson Scale</outcome>
      <timepoint>On days 2, 6, 10, 17, 21, 28, 35, 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Liver Function Tests</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haematology</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Function Tests</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Thyroid Function Tests</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Prolactin</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood glucose</outcome>
      <timepoint>On Days 2 and 42.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Provision of written informed consent. Young people under the age of 19 years admitted to the Youth Inpatient Unit YIU) with a psychotic disorder according to DSM-IV criteria.Subjects must have a chronic or intermittent psychosis with a documented clinical diagnosis of: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Major Depressive Disorder with psychotic features, or Bipolar I Disorder according to the criteria of DSM IV [18].</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>19</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with alcohol or substance dependence not in full remission. Previous and successful treatment with Quetiapine or Risperidone.History of non-response to atypicals.Patients who have taken Clozapine within the previous 60 days.A positive test for pregnancy.Sexually active females who are not on a medically validated contraceptive e.g. double barrier, oral contraceptives, DepoProvera.Any clinical significant medical condition that could affect required evaluation or increase the risk of adverse affects with treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Open Label Study</concealment>
    <sequence>Subjects are alternately allocated to either quetiapine or risperidone</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Harith Swadi</primarysponsorname>
    <primarysponsoraddress>Princess Margaret Hospital
Christchurch</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AstraZeneca</fundingname>
      <fundingaddress>Sydney, NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if treatment with quetiapine will improve young patients psychosis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital</ethicname>
      <ethicaddress>P.O. Box 800 Christchurch</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Harith Swadi</name>
      <address>Consultant Psychiatrist
Youth Inpatient Unit
Princess Margaret Hospital
PO Box 800
Christchurch</address>
      <phone>+64 3 3377800</phone>
      <fax />
      <email>harith.swadi@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Harith Swadi</name>
      <address>Consultant Psychiatrist
Youth Inpatient Unit
Princess Margaret Hospital
PO Box 800
Christchurch</address>
      <phone>+64 3 3377800</phone>
      <fax />
      <email>harith.swadi@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>